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Abstract  92 
Bone mineral density (BMD) assessed by DXA is used to evaluate bone health. In children, total 93 
body (TB) measurements are commonly used; in older individuals, BMD at the lumbar spine (LS) 94 
and femoral neck (FN) is used to diagnose osteoporosis. To date, genetic variants in more than 95 
60 loci have been identified as associated with BMD. To investigate the genetic determinants of 96 
TB-BMD variation along the life course and test for age-specific effects, we performed a meta-97 
analysis of 30 genome-wide association studies (GWAS) of TB-BMD including 66,628 individuals 98 
overall and divided across five age-strata each spanning 15 years. We identified variants 99 
associated with TB-BMD at 80 loci, of which 36 have not been previously identified; overall they 100 
explain approximately 10% of the TB-BMD variance when combining all age groups and 101 
influence the risk of fracture. Pathway and enrichment analysis of the association signals 102 
showed clustering within gene-sets implicated in the regulation of cell growth and SMAD 103 
proteins; overexpressed in the musculoskeletal system; and enrichment in enhancer and 104 
promoter regions. These findings reveal TB-BMD as a relevant trait for genetic studies of 105 
osteoporosis, enabling the identification of variants and pathways influencing different bone 106 
compartments. Only variants in ESR1 and close proximity to RANKL showed a clear effect 107 
dependency on age. This most likely indicate that the majority of genetic variants identified 108 
influence BMD early in life and their effect can be captured throughout the life course.  109 
Introduction 110 
Osteoporosis is a disease characterized by low bone mass and microarchitectural deterioration 111 
of bone tissue leading to increased risk of fracture1. It is diagnosed through the measurement 112 
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of bone mineral density (BMD) utilizing dual-energy X-ray absorptiometry (DXA), which is the 113 
single best predictor of fracture1.  114 
Bone is a dynamic tissue constantly undergoing resorption and formation. Bone mass increases 115 
steadily during childhood and markedly during adolescent growth2. Peak bone mass is attained 116 
at approximately the third decade of life. Thereafter, until about 50 years of age, BMD remains 117 
fairly stable, by virtue of the coupling between bone formation and resorption (e.g., bone 118 
remodeling). Subsequently, bone resorption exceeds the rate of bone formation, resulting in a 119 
decrease in BMD, particularly in women after the onset of menopause3.  120 
The International Society for Clinical Densitometry recommends performing DXA 121 
measurements at the lumbar spine, femoral neck and total hip to diagnose osteoporosis in 122 
postmenopausal women and men who are 50 years or older4. Consequently, studies of BMD 123 
determinants are frequently based on measurements at these skeletal sites. By contrast, for the 124 
assessment of bone health in children and adolescents, total body (excluding head) and lumbar 125 
spine are the preferred sites to minimize measurement artifacts resulting from changing areas 126 
in growing bones4. Nevertheless, in elderly individuals degenerative changes in the spine can 127 
give elevated BMD readings5. Moreover, total body DXA scans have been obtained in a number 128 
of adult research cohorts, primarily to assess body composition. Therefore, the total body BMD 129 
(TB-BMD) measurement is the most appropriate method for an unbiased assessment of BMD 130 
variation in the same skeletal site from childhood to old age. 131 
To date, nearly 80 independent genetic variants have been shown to be robustly associated 132 
with variability in bone parameters6-18. Most of these markers have been identified in studies 133 
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comprising tens of thousands of adult and elderly individuals with DXA-derived BMD 134 
measurements, although a few of them have been associated with BMD specifically in studies 135 
of pediatric cohorts8. Furthermore, several of the associated variants display significant site-136 
specific effects, possibly reflecting differences in bone composition across skeletal sites (e.g., 137 
cortical bone vs. trabecular bone) or differential response to mechanical loading8. Moreover, 138 
genetic studies on measures from peripheral quantitative computed tomography (pQCT) and 139 
bone quantitative ultrasound, which provide additional information regarding bone size, 140 
geometry and (micro) architecture identified genetic variants that may have specific effects on 141 
bone properties that are poorly captured by conventional DXA measurements 9-10.  142 
Given the complex physiological processes underlying age-related changes in BMD across the 143 
life course, it is possible that genetic studies in more refined age groups will reveal variants in 144 
unreported loci as well as age-specific genetic effects. Thus, the purpose of this study was to 145 
identify gene variants associated with TB-BMD across the life span and investigate possible 146 
differences of genetic effects across age periods. 147 
  148 
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Methods 149 
TB-BMD GWAS meta-analyses  150 
Study Populations 151 
Subjects 152 
This study comprised 30 epidemiological studies comprising ~66,628 individuals from 153 
populations across America, Europe, and Australia, with a variety of designs (Supplemental 154 
Data; Table S1) and participant characteristics (Table S2). In summary, most participants came 155 
from population-based cohorts of European ancestry (86%), two cohorts comprising African-156 
American individuals (2%) and other four studies holding a fraction of individuals from admixed 157 
background (14%). All research aims and the specific measurements have been approved by the 158 
correspondent Medical Ethical Committee of each participating study. Written informed 159 
consent was provided by all subjects or their parents in the case of children. 160 
BMD measurement 161 
Total body BMD (g/cm2) was measured by DXA following standard manufacturer protocols. As 162 
recommended by the International Society for Clinical Densitometry total body less head (TBLH) 163 
was the measurement used in pediatric cohorts4 (e.g., 0-15 years). Detailed information on the 164 
assessments performed by each study can be found in Table S1.  165 
GWAS data and imputation 166 
All individuals included in this study had genome-wide array data. Quality control of genotypes 167 
is summarized in Table S1. To enable meta-analysis, each study performed genotype 168 
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imputation using the cosmopolitan (all ethnicities combined) 1000 genomes phase 1 version 3 169 
(March 2012) reference panel, yielding ~ 30,000,000 SNPs for analysis. Three studies used the 170 
combined 1000 genomes and the UK10K reference panels as presented in Table S1. 171 
Association Analysis 172 
TB(LH)-BMD was corrected for age, weight, height and genomic principal components (derived 173 
from GWAS data), as well as any additional study-specific covariates (e.g. recruiting center), in a 174 
linear regression model. For studies with non-related individuals, residuals were computed 175 
separately by sex, whereas for family-based studies sex was included as a covariate in the 176 
model. Finally, residuals were inverse normal transformed.  The analyses were performed in 177 
each study for the overall population as well as in subgroups of individuals by age-strata, 178 
defined by bins of 15 years (i.e., 0-15 years, 15-30 years, 30-45 years, 45-60 years, and 60 or 179 
more years). SNP association was tested for autosomal variants, in which the additive effect of 180 
each SNP on the normalized BMD-residuals was estimated via linear regression. 181 
Quality control of TB-BMD association summary statistics  182 
A centralized quality-control procedure implemented in EasyQC19 was applied to all study-183 
specific files of association results to identify cohort-specific issues. We excluded variants if 184 
they had missing information (e.g., missing association P-value, beta estimate, alleles, allele 185 
frequency), or nonsensical values (e.g., absolute beta estimates or standard errors >10, 186 
association P-values >1 or <0; or imputation quality < 0; infinite beta estimates or standard 187 
errors); minor allele frequency (MAF) less than 0.5%; imputation quality scores <0.4 (Impute2) 188 
or <0.3 (Minimac). Moreover, variants were flagged if they had large allele frequency 189 
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deviations from reference populations (>0.6 for admixed studies and >0.3 for ancestry-190 
homogeneous studies). 191 
GWAS meta-analyses  192 
In the first instance, no exclusion criteria based on ancestry were applied for the meta-analysis 193 
(N=66,628).In addition, meta-analyses were carried out across age strata (minimum sample size 194 
per bin N=200 for each study) comprising: 1) 0-15 years (N=11,807), 15-30 years (N=4,180), 30-195 
45 years (N=10,062), 45-60 years (N=18,805), and 60 or more years (N=22,504). Further, 196 
summary data from cohorts of European ancestry only were meta-analyzed and used in 197 
subsequent analyses. We discarded variants present in less than three studies. Approximately 198 
23,700,000 markers (including SNPs and INDELS) were assessed for association. We applied the 199 
conventional genome-wide significance level (GWS, P<5x10-8) for SNP discovery.  200 
Assessment of Age-dependent effects  201 
We selected SNPs which were suggestively (12,567 SNPs, P<5x10-6) associated with BMD in the 202 
overall meta-analysis, present in at least 2 studies per age-bin and with MAF differences across 203 
these meta-analyses lower than 0.5. We clumped this dataset with an r2 ≥ 0.8, using as 204 
reference the most strongly associated SNPs with BMD and, pruning remaining SNPs within 0.7 205 
Mb of each other. Age-dependent effects were assessed using a meta-regression approach for 206 
1,464 SNPs obtained after this selection procedure. We ran a linear regression of the SNP effect 207 
estimates onto an intercept and the median age of each subgroup (e.g., each study stratified in 208 
age-bins). As proposed previously20, standard errors of the effect estimates of each subgroup 209 
were multiplied by the square root of the genomic inflation factor when it was greater than 1. 210 
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We performed the meta-regression using the Metafor package21, and any statistical evidence of 211 
linear association was corrected for multiple testing (Bonferroni correction; 0.05/1,464= 3.4x10-212 
5). The difference between beta-estimates in children vs. elderly meta-analyses (Pdiff) was 213 
tested using Easy-strata22.  214 
Approximate conditional meta-analyses 215 
Conditional analyses were undertaken based on the meta-analysis of the studies of European 216 
ancestry only (N=56,284). Only variants in the loci that reached GWS in this meta-analysis were 217 
assessed. The Rotterdam Study I (n=6,291) was used as reference for precise calculation of the 218 
linkage disequilibrium (LD) between the analyzed markers. We used an iterative strategy as 219 
implemented in GCTA23 to determine: 1) independence of association signals within loci 220 
discovered in our study, by means of stepwise model selection procedure per chromosome (--221 
massoc-slct routine); and 2) the novelty of the association signals discovered by our meta-222 
analysis with regard to variants reported in previous well-powered GWAS of different bone 223 
traits (Table S3). To this end, we performed the association analysis conditional on 78 variants 224 
present in our data and associated with different bone-traits (--massoc-cond routine). These 78 225 
SNPs were selected from different GWAS publications6-10;12-14 , assuring their independence to 226 
avoid collinearity issues.  227 
 228 
 229 
 230 
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Shared Genetic architecture of TB-BMD fracture and other traits  231 
LD score regression analyses  232 
We used the LD score regression package to estimate the heritability of TB-BMD and rule out 233 
that our results were a product of bias (e.g., residual population stratification or cryptic 234 
relatedness). LD score regression uses GWAS summary statistics and assesses the SNP-235 
heritability based on the expected relationship between linkage disequilibrium (LD) of 236 
neighboring SNPs and strength of association under a polygenic model24. As this methodology 237 
relies on the LD structure throughout the genome, we restricted this analysis to summary 238 
statistics from the meta-analysis of cohorts comprising only individuals from European 239 
ancestry. We used the publicly available, pre-computed LD structure data files specific to 240 
European populations of the HAPMAP 3 reference panel. An extension of this method allows 241 
estimating the genetic correlation between two traits25. This can be performed in the LDhub 242 
pipeline, a web utility which gathers data from many different GWAS meta-analysis26. From the 243 
199 traits, currently available in the website, we have restricted our analysis to those traits 244 
whose heritability z-scores were larger than 4 and were analyzed only in European ancestry 245 
individuals (following the recommendations in the LD score software website (Web 246 
Resources)). Additionally, we incorporated data from a recent GWAS meta-analysis of any-type 247 
of fracture in individuals from European ancestry (N= 264,267; 37,778 cases) (K.T, unpublished 248 
data). In total, we assessed the genetic correlation between TB-BMD and 74 traits.  249 
 250 
 251 
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Mendelian randomization analysis  252 
We undertook a two-sample Mendelian randomization approach27 to estimate the causal effect 253 
of TB-BMD on any-type of fracture in the Europeans samples. In short, we constructed a score 254 
based on the independent genetic variants from the TB-BMD meta-analysis (European set and 255 
excluding secondary signals), whenever the selected variant was not present in the fracture 256 
meta-analysis, the second variant with the lowest p-value in the locus (P<5x10-8) and r2 > 0.8 257 
was used as proxy. Thereafter, estimates derived from the TB-BMD summary statistics were 258 
pooled using methods similar to inverse-variance weighted fixed meta-analysis using the meta 259 
R-package (Web Resources). 260 
Search for biological and functional knowledge of the identified association regions 261 
For all those SNPs outside a 500Kb window from previously known bone associated SNPs we 262 
did a literature search in PubMed and Web of Science to evaluate if nearby genes (within 263 
500Kb) were known to play a role in bone metabolism. Also, we determined if the annotated 264 
genes underlie any human Mendelian disorder with a skeletal manifestation, had knockout 265 
mouse models with a skeletal phenotype or were annotated to pathways critical to bone 266 
metabolism. Genomic annotation for all SNPs was made based on UCSC hg19.  267 
DEPICT analyses  268 
We used DEPICT28, a recently developed tool to prioritize genes at the associated regions, 269 
define possible pathways by enrichment testing, and identify tissue and cell types in which 270 
genes from loci associated with TB-BMD. The methodology first selects all lead SNPs below a 271 
certain threshold with respect to a target P-value. We tested both the complete set of GWS 272 
12 
 
SNPs and the subset of those mapping only to loci not previously reported. Enriched gene-set 273 
were group based on the degree of gene overlap into ‘meta gene-sets’ as proposed earlier29, 274 
and their correlation visualized using Cytoscape 3.4 (Web Resources).  275 
Functional annotation to microRNA binding sites 276 
We used the PolymiRTS29, miRdSNP30, and microSNiPer31 databases to obtain a list of variants 277 
located in predicted microRNA binding sites on the 3’UTRs of genes, as described in detail 278 
elsewhere32. In summary, index SNPs (most associated variant) of the GWS loci were submitted 279 
to SNAP (Web Resources) to retrieve their high LD proxy SNPs (with r2 > 0.8, limit distance 500 280 
kb, and CEU panel) in the 1000 genomes project. The resulting list of SNPs was annotated to the 281 
list of microRNA binding site variants obtained from the above mentioned publicly available 282 
databases. 283 
Functional enrichment analysis of trait-associated variants 284 
GWAS Analysis of Regulatory or Functional Information Enrichment with LD correction 285 
(GARFIELD)33 was used to characterize the putative functional contribution of TB-BMD 286 
associated variants mapping to non-coding regions. GARFIELD employs a non-parametric 287 
analysis to calculate fold enrichment values for regulatory marks, at given significance 288 
thresholds and then tests them for significance via permutation testing while accounting for LD, 289 
MAF and local gene density33. We used data regarding DNase I hypersensitive sites, 290 
transcription factor binding sites, histone modifications and chromatin states (ENCODE and 291 
Roadmap Epigenomics) from 424 cell types and tissues to capture and characterize possible 292 
cell-type-specific patterns of enrichment, as provided in the GARFIELD software (Web 293 
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Resources). Fold enrichment statistics were tested at the four different significance thresholds 294 
(i.e., 1×10–8, 1×10–7, 1×10–6 and 1×10−5). Multiple-testing correction was performed on the 295 
effective number of annotations used, using the default P-value threshold of 1×10−4. 296 
Knockout animal models and gene expression in bone cells  297 
Animal models survey  298 
We surveyed databases from The International Mouse Phenotyping Consortium34 together 299 
with The International Knockout Mouse Consortium35 to identify knockout models of 300 
candidate genes resulting in skeletal phenotypes. Furthermore we mined data from The 301 
Origins of Bone and Cartilage Disease (OBCD) project36, specialized in murine skeletal 302 
phenotypes including Digital X-ray microradiography on femurs and tail vertebrae, Micro-CT 303 
analysis, femur three-point bend test load–displacement curves and tail vertebrae 304 
compression testing from knockout mice and wild-type controls at 16 weeks of age.  305 
Gene expression in murine bone cells 306 
Gene expression profiles of candidate genes were examined in primary mouse osteoblasts 307 
undergoing differentiation and bone marrow derived osteoclasts. To study murine 308 
osteoblasts, pre-osteoblast-like cells were obtained from neonatal calvaria collected from 309 
C57BL/6J. Next Generation RNA sequencing using an Illumina HiSeq 2000 was used to 310 
evaluate the transcriptome every two days from day 2 to 18 days post osteoblast 311 
differentiation7. Expression of genes in murine osteoclasts was determined using publicly 312 
available data obtained using Next-Gen RNA-sequencing applied to bone marrow derived 313 
osteoclasts obtained from 6-8 week old C57BL/6 mice37.  314 
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Gene expression in human bone cells  315 
Gene expression profiles of candidate genes were examined in human bone marrow derived 316 
mesenchymal stem cells differentiated into osteoblast. Total RNA (n=3) was isolated at day 0 317 
(MSCs) and day 4 of osteoblast differentiation38. Also, RNA was isolated during osteoclast 318 
differentiation. Peripheral blood mononuclear cells derived from buffy coats (Sanquin, 319 
Amsterdam, the Netherlands) were seeded in 96-well plates (5x105 cells per well) as 320 
previously described39 Total RNA (n=3) was isolated using Trizol at day 0 (PBMCs) and at day 321 
7 of osteoclast differentiation. Illumina HumanHT-12 v3 BeadChip human whole-genome 322 
expression arrays were used for expression profiling. The quality of isolated RNA was 323 
assessed on a 2100 Bioanalyzer (Agilent Technologies). Data were analyzed as described in 324 
detail previously38. Genes were designated as being expressed when at least one probe 325 
coding for the gene was significantly present in at least 2 of the 3 biological replicates.  326 
Results 327 
TB-BMD GWAS meta-analyses  328 
Analyses including all age-strata 329 
Our meta-analysis of TB-BMD GWAS summary statistics (N=66,628) identified variants in 76 330 
independent loci associated with TB-BMD at a genome-wide significant (GWS, P<=5x10-8) level 331 
(Figure 1, Table S4). Overall, there was no evidence of a strong inflation (genomic inflation 332 
factor () of 1.08, Figure S1). Yet, inflation was observed in the range of common variants 333 
(0.2>MAF<0.5, =1.19) due to polygenicity (LD score regression intercept = 1.007). In our 334 
results, one of the signals mapping to LDLRAD3 was driven entirely by individuals of African 335 
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background (MAF=0.043 in YRI panel) since the two associated variants are monomorphic in all 336 
other populations. The low allele frequency of this variant in our study (MAF= 0.025) and our 337 
limited statistical power (N=6,748) in non-European samples warrants independent replication 338 
efforts to exclude the possibility of a false-positive association.  339 
In addition, a meta-analysis comprising 56,284 individuals of European ancestry (~84% of the 340 
study population) identified variants in two additional GWS loci (Figures S1-S2, Table S5). 341 
Association signals mapping to these loci were close to the GWS threshold in the overall meta-342 
analysis (P=1x10-7) and showed no evidence of heterogeneity (Phet>0.1). One of them, in 343 
12q24.21 (MED13L), has not been previously associated with bone parameters (Table 1, Figure 344 
S3), while the other in 21q22.13 (CLDN14), is not fully independent from the previously 345 
reported hip-BMD association signal13 (Table S5).  346 
Of the 78 identified loci, variants in 35 (45%) were not located within 500 kb of known 347 
association signals nor in regions of extended LD with them (Table 1, Figure S4). Index SNPs at 348 
these 35 loci were, in general, common non-coding variants. Twenty-two of these, are located 349 
in close proximity to genes likely to influence bone metabolism as shown by previous functional 350 
studies (Table 1, Figure S3), including CSF1 ([MIM 120420] important for osteoclast 351 
differentiation40) and SMAD3 ([MIM 603109] a critical component of the TGF-beta signaling 352 
pathway41). Across these 35 signals, 31 of the index SNPs were nominally associated (P<0.05) 353 
with either lumbar spine or femoral neck BMD in the same direction as in the previously 354 
published GEFOS GWAS meta-analysis7 (Table 1). This comparison was not possble for the 355 
rs113964474 variant, because it was not available in the GEFOS study. Moreover, we found 356 
directionally-concordant effect estimates (P < 0.05) for 73 of the 78 index SNPs of known bone 357 
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association signals (Table S3). The markers which failed to replicate in our study were either 358 
previously associated with lumbar spine BMD but not femoral neck BMD (rs3905706 [MPP7, 359 
10p12.1] and rs1878526 [INSIG2, 2q14.2]), associated specifically with the hip trochanter and 360 
intertrochanteric subregions (rs1949542 [RP11-384F7.1, 3q13.32]), or associated with BMD 361 
only in women (rs7017914 [XKR9, 8q13.3]) or only in children (rs754388 [RIN3, 14q32.12]).  362 
Age-dependent effects  363 
Meta-analyses across age strata resulted in the identification of variants mapping to 2 364 
additional loci that were not detected in the overall meta-analysis (Figure S5; Table S6). In 365 
children (age group 0-15 years), the previously known 14q32.12 locus8, harboring RIN3 366 
(rs72699866, P=1x10-8); and in the middle-aged (age group 45-60 years), a signal in the 19q12 367 
locus mapping in the vicinity of  TSHZ3 (rs6510186, P=3.1x10-8) were identified. The rs72699866 368 
variant leading the RIN3 signal in the youngest age stratum showed no evidence of association 369 
(P=0.16) and high heterogeneity (Phet=6.6x10
-5) in the overall meta-analysis. In fact, the effect of 370 
rs72699866 decreased significantly with age (Ptrend=1.69x10
-9) (Figure S6) and showed a 371 
significant difference between the two extreme groups, i.e. children vs elderly (β0-15=0.099 372 
[0.066, 0.134]; β>60=-0.035 [-0.060, -0.010]; Pdiff=4.32x10
-10). In contrast, the rs6510186 variant 373 
[19q12] showed nominal evidence of association and heterogeneity in the overall meta-analysis 374 
(P=0.02; Phet=0.03). Nevertheless, no clear pattern of age-dependency was identified (P=0.2) for 375 
this SNP (Figure S6). 376 
We also applied meta-regression analysis and found that variants mapping to 42 different loci 377 
showed nominally significant age dependent effect (P<0.05) (Table S7, Figure S7). In summary, 378 
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27 (64%) of the loci showed stronger effects in the older age groups. Of these, variants in the 379 
6q25.1 (ESR1) and 13q14.11 (RANKL) loci remained significant after multiple-testing correction 380 
(P<3.4x10-5) (Figure 2); while variants in 6p21.1 (RUNX2, rs148460475), 15q21.2 (CYP19A1, 381 
rs2414098), 17q21.31 (MEOX1, rs74835612) and 11p15.1 (SOX6, rs11822790) were only 382 
suggestive at P<1x10-3.  383 
Conditional association analyses  384 
The step-wise conditional approach included studies comprising only individuals of European 385 
ancestry, as the method used relies on appropriate representability of the LD reference. Of the 386 
76 GWS loci identified in the overall analysis, variants in 57 (19 previously unreported) loci were 387 
also GWS in the European-only analysis (Figure S2), likely a consequence of the lower power in 388 
this subgroup. We identified 81 SNPs independently associated with TB-BMD mapping to 58 389 
different loci (one European-specific), 18 of which depicted multiple distinct signals attaining 390 
GWS (Table S8). These independent variants together explained 10.2% of TB-BMD variance. 391 
This proportion is slightly higher than the 7.4% TB-BMD variance explained by the 78 known 392 
variants associated with bone traits. Moreover, we identified independent signals in 13 of the 393 
78 known bone loci after conditional analyses. (Figure S2; Table S8). 394 
Shared Genetic architecture of TB-BMD, fracture and other traits  395 
SNP-heritability of TB-BMD in the European samples was estimated to be 0.259 (SE 0.017). TB-396 
BMD was highly genetically correlated with BMD measured at other skeletal sites (ρ>0.9). 397 
Among the non-BMD traits, all-type of fracture showed the highest correlation [ρ=-0.61 398 
(P=1.6x10-27)]. The MR approach indicated a strong causal relation where per 1 standard 399 
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deviation decrease in genetically determined TB-BMD there is 56% increase in the risk of 400 
fracture (Odds ratio 1.56 [1.50-1.62]). Other anthropometric, metabolic and disease traits 401 
showed significant (yet weak) correlation with TB-BMD (Table S9, Figure 3). In contrast, other 402 
established risk factors for osteoporosis such as menopause or age of menarche showed no 403 
significant genetic correlation with TB-BMD. 404 
Biological and functional knowledge of the genes in BMD-associated loci 405 
Loci not previously reported and their potential role in bone metabolism are summarized in 406 
Table 1. Several loci harbor genes implicated directly in bone metabolism (SLC8A1 [MIM 407 
182305], PLCL1 [MIM 600597], ADAMTS5 [MIM 605007]), affecting osteoblast or osteoclast 408 
differentiation and activity (CSF1 [MIM 120420],, DUSP5 [MIM 603069], SMAD3 [MIM 603109], 409 
SMAD9 [MIM 603295], CD44 [MIM 107269]), participating in Wnt signaling (FZD7 [MIM 410 
603410], TCF7L1 [MIM 604652]), or regulating processes such as manganese or calcium 411 
absorption (GCKR [MIM 600842], DGKD [MIM 601826], SLC30A10 [MIM 611146]) among others 412 
40-61; while genes in at least 14 loci exert a potential novel role in bone biology. Rodent 413 
knockout models of several genes in the implicated loci, show an altered skeletal phenotype 414 
(e.g., ostoepetrosis [Csf140], increased bone resorption [Aqp150, Cyp19a157, Cd4453], impaired 415 
skeletogenesis [Apc49, Runx160, Smad341], deformities in the axial skeleton [Btg162, Atpaf263]). 416 
Whereas an effect on bone can be inferred for genes in other associated loci, for example, 417 
CYP19A1 [MIM 107910] in 15q21.2 is an estrogen synthesis gene, being estrogen a key 418 
compound for bone maturation and maintenance, and ZKSCAN5 [MIM 611272] in 7q22.1 is 419 
associated with circulating dehydroepiandrosterone sulphate (DHEAS) levels51. DHEAS levels 420 
are positively correlated with BMD in adults and post-menopausal women64. Across these loci, 421 
19 
 
not previously reported as associated with BMD variation, we identified six exonic variants 422 
associated with TB-BMD, three of which were nonsynonymous variants all cataloged as benign 423 
both by SIFT and polyphen2. We also identified 53 GWS coding variants in known loci, of which 424 
33 are non-synonymous (Table S10). Only a low-frequency variant in LRP5 [MIM 603506], 425 
rs4988321/A (11:68174189, MAF=0.04), has a clinical annotation, constituting a homozygous G-426 
to-A transition variant identified in a person with osteoporosis-pseudoglioma syndrome (OPPG 427 
[MIM 259770])65.  428 
DEPICT analyses 429 
Based on the overall meta-analysis, 53 genes were prioritized (FDR<0.05), 15 of them mapping 430 
to loci not previously described (Table S11). Cells and tissues from the musculoskeletal system 431 
presented the largest enrichment of gene expression within the associated loci (Figure 4). 432 
These genes were overrepresented in 182 pathways clustered in 25 ‘meta gene-sets’ (Table 433 
S12). The large majority of the clusters are involved in musculoskeletal development and bone 434 
homeostasis (Figure 4). The most significant of these implicated the regulation of cell growth, 435 
and the TGFB signaling pathway and its mediating SMAD proteins.  436 
Restricting the DEPICT analysis to the subset of not previously reported associated regions 437 
resulted in significant enrichment of genes expressed in the musculoskeletal and immunological 438 
systems (Figure S8). Genes mapping to these loci were overrepresented in the SMAD binding 439 
pathway and TGFBR2 PPI (protein-protein interaction) subnetwork (FDR<0.05).  440 
Functional annotation to microRNA binding sites 441 
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We then assessed if the index SNPs of the 80 GWS loci detected in the main and subsequent 442 
GWAS (or their proxies in strong LD; r2>0.8) were located in predicted microRNA binding sites 443 
within the genes’ 3’UTRs and thus, were expected to disrupt the regulation of gene expression 444 
(Table S13). The index SNP within the 3’UTR of ZKSCAN5 (mapping to a locus not previously 445 
identified), rs34670419 (MAF=0.04), is predicted to create a binding site for miR-382-3p, a 446 
microRNA which is expressed in osteocytes and has been recently shown to be involved in 447 
osteogenic differentiation66. In addition, eight proxy SNPs (mapping to PSMD13, ABCF2, 448 
GALNT3, PKDCC, REEP5, PPP6R3, AAGAB and TOM1L2) are predicted to influence the binding of 449 
microRNAs to transcripts of their host gene.  450 
Functional enrichment analysis of trait-associated variants 451 
As typically found in GWAS, the great majority of identified associations emerged from non-452 
coding common variants and hold no direct annotation to molecular mechanisms. 453 
To assess if there is relative enrichment of regulatory genomic marks underlying the associated 454 
variants in a cell-specific context, we used GARFIELD33. We found relative ubiquitous 455 
enrichment for TB-BMD variants (Empirical P<2.4x10-4) in DNase I hypersensitive sites across 456 
the different cell types (Figure S9). Further, we found higher levels of fold-enrichment for 457 
enhancers (median 3.6, range [2.7, 4.4]) and promotors (median 3.2, range [2.9, 3.5]) than for 458 
transcribed regions (median 1.8, range [1.5, 2.2]). 459 
Gene expression in bone cells and knockout animal models 460 
From the 53 genes prioritized by DEPICT only 49 had a mouse orthologue (Table S14). From 461 
these genes, only Mepe (osteocyte-specific) and Foxl1 were not expressed in murine osteoblast 462 
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or osteoclast. Moreover, 61% of the prioritized genes were expressed in human cells in vitro 463 
during osteoblast or osteoclast differentiation (Table S14). AQP1 was the only prioritized gene 464 
mapping to a locus not previously reported showing no expression in the human bone cells 465 
differentiation experiments.  466 
Knockout models were widely available in at least one of the different databases assessed. 467 
Nevertheless in-depth bone phenotyping performed under the OBCD project was only available 468 
for four knockout models (Table S15). Two of these, DUSP5 and CD300LG showed no significant 469 
bone phenotype. The TCF7L1 knockout model only showed lower cortical diameter in the femur 470 
without other clear bone phenotype. Nevertheless, TCF7L1 was shown to be expressed during 471 
osteoblastogenesis. Conversely, homozygous knockout for CREB3L1 showed a clear bone 472 
phenotype consisting of low BMC both at the vertebrae and femur together with a strong 473 
trabecular and cortical phenotype affecting bone strength (Figure S10). CREB3L1 maps to 474 
11p11.2, a previously identified BMD locus6 harboring ARHGAP1 and LRP4 as candidates to 475 
underlie the GWAS signal in a region of extended LD.  476 
Discussion  477 
This meta-analysis of TB-BMD comprising up to 66,000 individuals identified variants in 36 loci 478 
not previously reported and replicated at GWS level several association signals identified by 479 
GWAS of diverse bone phenotypes. Bioinformatics analyses suggest enrichment of these 36 loci 480 
for genes expressed in the musculoskeletal system, and solidly represented in the SMAD 481 
binding pathway and the TGFBR2 PPI subnetwork. We also demonstrate that for variants in few 482 
loci the size of the effect is age dependent; variants in two loci (RIN3 and TSHZ3) were 483 
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identified only by the age-stratified analyses despite less power (smaller sample size); while for 484 
variants in two other loci (ESR1 and RANKL) there was significant evidence of age heterogeneity 485 
derived from a meta-regression of the genetic effects with age. Our results strengthen the 486 
evidence that genetic variants influence BMD from a young age and support the value of peak 487 
bone mass as an important determinant of bone health later in life.  488 
Traditionally, DXA-BMD measurements performed at sites of high fracture risk (i.e., femoral 489 
neck, lumbar spine and forearm) have been used in genetic epidemiological investigations of 490 
bone health in adults. Instead, we have used BMD measurements derived from total body 491 
scans. Not only do we show a high overlap of association signals with previous GWAS of 492 
different bone traits, including DXA, pQCT and ultrasound measurements, but we have also 493 
identified unreported loci. Five known associations failed to replicate in our studies, even 494 
though we cannot discard these associations constitute false-positives, these results might also 495 
indicate that variants whose effect is highly specific to skeletal sites, skeletal properties, sex or 496 
age groups cannot be detected in our TB-BMD meta-analysis. It is plausible that more variants 497 
of this type exist and will be discovered as site-specific BMD meta-analyses are performed in 498 
increasingly powered settings. Furthermore, the genetic correlation of TB-BMD with BMD 499 
measured at other sites was close to one. Whilst, we found that a decrease of one standard 500 
deviation in the genetically determined TB-BMD resulted in at least 50% higher odds of 501 
suffering a fracture. Significant genetic correlations with other traits (i.e., BMI, IGF1 and 502 
ulcerative colitis) reflect the systemic context of skeletal biology and merit further study by 503 
future efforts to elucidate the underlying mechanisms. 504 
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Genes in the associated loci were highly expressed in the musculoskeletal system and 505 
overrepresented in gene-sets related to bone development. The prioritized gene CREB3L1 [MIM 506 
616215] in 11p11.2 observed a clear bone phenotype in our mouse knockout model, which 507 
corroborates the findings of previous work showing substantial rescue of CREB3L1 deficiency 508 
with bisphosphonates and its critical role for bone formation67. This locus characterized by 509 
extended LD, also harbors LRP4 [MIM 604270] whose knockout model presents with increased 510 
trabecular and cortical bone mass68. This is in line with our conditional analysis identifying 511 
multiple independent signals in the region making it likely that both genes are influencing bone 512 
biology. Altogether, we demonstrated that TB-BMD offers a powerful alternative to identify 513 
genetic variants associated with bone metabolism.  514 
Variants mapping to 14q32 harboring RIN3 [MIM 610223] were only associated at a GWS level 515 
in children (i.e., <15 years), and were only nominally significant in the elderly group (i.e., >60 516 
years). This age-related heterogeneity may explain why this locus has not been detected in 517 
BMD meta-analyses in adults, although being identified in relation to pediatric BMD8 and 518 
Paget`s disease (PDB [602080]) GWAS69. In addition, another signal mapping to 19q12 519 
harboring TSHZ3 [MIM 614119] was significant in adults aged 45-60 years but not in other age 520 
groups analyzed or in previous studies, alluding to a false-positive association, thus replication 521 
of this finding is necessary.  522 
Our analyses revealed variants in the 6q25.1 (ESR1) and 13q14.11 (RANKL) loci demonstrating 523 
the most compelling evidence for age-modulation effects. The 6q25.1 locus harboring ESR1 524 
[MIM 133430], an important genetic factor in normal BMD variability, was not associated with 525 
BMD in children below 15 years of age, where the largest cohorts (i.e., Avon Longitudinal Study 526 
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of Parents and Children (ALSPAC) and the Generation R Study) comprise predominantly pre-527 
pubertal children. As levels of estradiol before puberty are low70, a negligible effect of ESR1 528 
variants on BMD is expected. Likewise, in mouse models the expression of RANKL [MIM 529 
602642] in bone is markedly increased with advancing age from young to adult and related to 530 
bone loss71. Accordingly, variants influencing RANKL expression show a larger effect later in life. 531 
In general, a substantial heterogeneity of the genetic effects in the overall meta-analysis was 532 
explained by age, nevertheless, the inclusion of larger sample sizes (avoiding age exclusion 533 
criteria and incrementing statistical power) leveled off the loss of power due to the 534 
heterogeneity of the genetic effects.     535 
In brief, variants with evidence of age-specific effects were exceptional in our study. These 536 
results might reflect a lack of statistical power as only SNPs showing suggestive evidence 537 
(P<5x10-6) of association with TB-BMD in the overall meta-analysis were tested for age-specific 538 
effects. This selection criteria aimed to include SNPs whose heterogeneity might have 539 
hampered their statistical significance in the overall meta-analysis, and at the same time 540 
maximize the power to discover variants with real age-dependet effects. Alternatively, these 541 
results indicate that most of the genetic variants identified so far, by us and others, influence 542 
BMD from early ages onwards, and their effect persist throughout the life course. However, 543 
variants in 27 of the 42 loci (64%) showing nominal evidence for age dependent effects had 544 
larger effects in the older groups. Nonetheless, this requires careful interpretation given the 545 
uneven sample sizes between the age groups and the criteria to select markers for the meta-546 
regression based on significance in the overall meta-analysis. Collectively, this argues in favor of 547 
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enlarging studies focused on younger populations –where the statistical power is still restricted 548 
– to discover additional genetic variants influencing BMD.   549 
Our study has some limitations. A key disadvantage of our design is that we group the data 550 
based on age spans rather than life stages. Crucial information for this assesment, such as 551 
puberty onset in children and adolecents or menopausal status in the adults, was not available 552 
across the majority of the cohorts. Other strategies like using shorter age spans will resulted in 553 
even less statistical power of the discovery setting. Similarly, despite the large sample size of 554 
our study, we identified very few variants in the low-frequency spectrum (MAF <5%) indicating 555 
that comprehensive surveys of rare variation influencing BMD still require even larger sample 556 
sizes, on top of better resources for imputation of the rarer variants, possibly needing 557 
population-specific references. Such strategies will be key to explain a larger fraction of the 558 
genetic variability of BMD phenotypes, as illustrated for other traits such as height or BMI72. 559 
Moreover, the identified SNPs are in their vast majority, non-coding variants, raising the 560 
possibility that the causal genes are different from the candidate genes we have prioritized 561 
based on the current biological knowledge and bioinformatic prediction tools. Additional 562 
functional studies are required to determine the potential role of the genes in the identified 563 
loci.  564 
In conclusion, we performed a genome-wide survey for association with DXA derived TB-BMD, 565 
combining data from five age groups including children and older individuals. In contrast to 566 
previous large-scale meta-analyses6;7, we used DXA derived TB-BMD rather than measurements 567 
on specific skeletal sites prone to fracture to identify genetic factors influencing BMD variation. 568 
We demonstrate that TB-BMD is a valid phenotype for this purpose, as we replicated more than 569 
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90% of the previously reported signals. Most importantly, we identify variants in 36 loci 570 
associated with TB-BMD not previously reported by previous GWAS of bone phenotypes. Our 571 
results show steadiness in the magnitude of the genetic effects on BMD for most of the BMD-572 
associated variants. While the contrasting skeletal physiology across different age periods is 573 
well established (i.e. endochondral ossification, linear growth, modelling, 574 
remodeling, etc.), peak bone mass acquisition remains the major determinant of variability at 575 
any age. These findings strongly support the importance of the bone accrual process in the 576 
definition of BMD status and fracture susceptibility throughout the life course.   577 
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Figure Titles and Legends 
 
 
Figure 1. Manhattan plot of association statistics (-log10(P-values)) for TB-BMD overall meta-analysis. Each dot 
represents a SNP and the x-axis indicates its chromosomal position (built 37 NCBI). Red dots represent SNPs at 
GWS loci that are not within ±500Kb of leading SNPs in previous GWAS with different bone traits. Dashed 
horizontal red and yellow lines mark the GWS threshold (P<5x10
-8
) and suggestive threshold (P<1x10
-6
), 
respectively. Novel loci in the only-CEU analysis are not shown. 
 
Figure 2. Age dependence of the genetic variant effect in the meta-regression. The panels display leading SNPs 
from two loci exhibiting significant evidence for age influences. Heterogeneity P-values (Phet) are reported for the 
overall meta-analysis. In the left panels, each circle represents a study subgroup (i.e., study divided in age strata), 
with the circle size proportional to the inverse variance of the SNP main effect. In the right panels, forest plots 
display estimates obtained from each age-bin meta-analysis, with the symbol size proportional to the inverse 
variance of the SNP main effect.  
 
Figure 3. Genetic correlations between TB-BMD and other traits and diseases. Calculation was based on the 
summary statistics of the only-European meta-analysis (N=56,284) and estimated by LD score regression 
implemented in LDHub. The diagram only show traits whose correlation with TB-BMD was significant (P<0.05). 
 
Figure 4. Depict results for gene-set and cell/tissue enrichment analyses. Top panel: 25 Meta gene-sets were 
defined from similarity clustering of significantly enriched gene sets (FDR<5%). Each Meta gene-set was named 
after one of its member gene sets. The color of the Meta gene-sets represents the P-value of the member set. 
Interconnection line width represents the Pearson correlation ρ between the gene membership scores for each 
Meta gene-set (ρ < 0.3, no line; 0.3 ≤ ρ < 0.5,narrow width; 0.5 ≤ ρ < 0.7, medium width; ρ ≥ 0.7, thick width). 
Bottom panel: Bars represent the level of evidence for genes in the associated loci to be expressed in any of the 
209 Medical Subject Heading (MeSH) tissue and cell type annotations. Highlighted in orange are these cell/tissue 
types significantly (FDR<5%) enriched for the expression of the genes in the associated loci.  
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Table 1. Index SNPs of loci not previously associated with BMD. Variants associated with TB-BMD in the all-ages combined meta-analysis that map outside +/- 500 Kb of known 
index SNPs of genetic associations with different bone traits. Genomic coordinates are on build 37 of the human genome. Notes refer to annotation based on the closest gene.  
Associations with Lumbar Spine (LS) and Femoral Neck (FN)-BMD 
10
. Beta coefficients and allele frequencies (EAF) are reported for the A1 allele 
CHR BP rsnumber Locus A1 A2 EAF Effect P N annotation closest gene Notes LS-beta LS-P FN-beta FN-P 
1 8422676 rs2252865 1p36.23 T C 0.32 -0.033 4.72E-08 66075 intronic RERE Novel biology -0.019 0.043 -0.025 0.002 
1 110475971 rs7548588 1p13.3 T C 0.61 -0.037 9.29E-09 66240 intergenic CSF1  Osteoclast differentiation40 -0.030 0.001 -0.022 0.005 
1 220038825 rs185048405 1q41 T C 0.54 0.042 3.07E-09 66540 intronic  SLC30A10 Manganese transport42 -0.035 0.076 -0.003 0.878 
2 27741072 rs780096 2p23.3 C G 0.44 -0.031 4.58E-08 66578 intronic  GCKR Calcium regulation43, hepatic traits44 -0.014 0.129 -0.017 0.029 
2 40630678 rs10490046 2p22.1 A C 0.76 0.043 1.43E-10 65961 intronic SLC8A1  Bone mineralization45 0.015 0.162 0.021 0.025 
2 68962137 rs10048745 2p13.3 A G 0.25 -0.039 6.44E-09 66565 5'-UTR ARHGAP25 Novel biology -0.050 1.03E-06 -0.036 5.21E-05 
2 85484818 rs11904127 2p11.2 A G 0.55 -0.032 2.65E-08 66561 intronic TCF7L1 Factors in Wnt signaling46 -0.021 0.023 -0.015 0.054 
2 198874006 rs1595824 2q33.1 T C 0.47 0.034 2.65E-08 60171 intronic PLCL1 Negative regulation of bone formation47 0.022 0.201 0.052 2.20E-04 
2 202799604 rs2350085 2q33.2 T C 0.87 -0.064 3.80E-14 66412 intergenic FZD7 Factors in Wnt signaling48 -0.042 0.002 -0.044 1.96E-04 
2 234303405 rs838721 2q37.1 A G 0.44 -0.031 4.48E-09 65516 intronic DGKD Calcium regulation43 -0.016 0.070 -0.014 0.068 
5 112221869 rs818427 5q22.2 T C 0.31 0.034 2.37E-08 66592 intronic APC Bone metabolism49 0.004 0.645 0.008 0.327 
5 122847622 rs11745493 5q23.2 A G 0.75 0.044 7.75E-12 66597 promoter CSNK1G3 Novel Biology 0.010 0.326 0.025 0.005 
7 27989403 rs757138 7p15.1 T G 0.69 -0.035 3.33E-08 66043 intronic JAZF1 Novel Biology -0.016 0.126 -0.025 0.004 
7 30957702 rs28362721 7p14.3 T C 0.18 -0.059 6.71E-14 66274 intronic AQP1  Bone metabolism50 -0.037 0.002 -0.049 1.39E-06 
7 50901491 rs1548607 7p12.1 A G 0.69 0.036 4.18E-08 66564 intergenic GRB10 Novel biology 0.034 5.59E-04 0.005 0.517 
7 99130834 rs34670419 7q22.1 T G 0.04 -0.088 1.09E-08 66336 3'-UTR ZKSCAN5 DHEAS and aging mechanisms51 -0.127 9.28E-08 -0.080 8.19E-05 
10 112245400 rs73349318 10q25.2 A T 0.87 -0.047 2.68E-08 66341 intronic DUSP5  Osteoclast differentiation52 -0.042 0.001 -0.051 8.76E-06 
10 124015986 rs10788264 10q26.13 A G 0.48 -0.034 2.61E-09 66565 intergenic TACC2 Novel Biology -0.030 9.64E-04 -0.029 1.29E-04 
11 242859 rs55781332 11p15.5 A G 0.78 -0.055 8.07E-16 66198 intronic PSMD13 Novel Biology -0.046 1.76E-05 -0.026 0.005 
11 35083633 rs2553773 11p13 C G 0.41 -0.037 1.49E-10 66619 intergenic CD44 Osteoclast activity53 -0.015 0.101 -0.015 0.054 
11 35981346 rs113964474* 11p.13* A G 0.03 0.485 1.41E-08 6748 intronic LDLRAD3 Novel Biology . . . . 
11 69299537 rs4980659 11q13.3 C G 0.52 0.033 1.16E-08 66537 intergenic CCND1 Target of Wnt signalling54 0.039 1.58E-05 0.023 0.003 
11 121913230 rs725670 11q24.1 A G 0.38 -0.032 3.61E-08 66565 intergenic BLID Novel Biology -0.020 0.028 -0.011 0.172 
12 90334829 rs10777212 12q21.33 T G 0.35 0.045 5.05E-14 66619 intergenic ATP2B1 Calcium absorption55 0.028 0.003 0.021 0.010 
12 116555786 rs73200209** 12q24.21 A T 0.80 0.045 2.51E-08 51240 intronic MED13L Novel biology 0.030 0.167 0.036 0.044 
13 37487021 rs556429 13q13.3 A C 0.23 0.039 1.46E-08 66504 intronic  SMAD9 Osteoblast differentiation56 0.023 0.027 0.013 0.135 
15 38340874 rs12442242 15q14 A  G 0.85 -0.051 4.94E-10 66403 intergenic TMCO5A Novel Biology -0.046 3.03E-04 -0.047 2.26E-05 
15 51537806 rs2414098 15q21.2 T C 0.39 -0.033 1.99E-08 66562 intronic CYP19A1 Estrogen byosynthesis57 -0.034 0.007 -0.038 0.001 
15 67420680 rs1545161 15q22.33 A G 0.56 0.041 1.06E-12 66004 intronic SMAD3 Osteoblast differentiation41 0.034 1.27E-04 0.035 5.78E-06 
17 17804725 rs8070128 17p11.2 T C 0.58 -0.039 1.98E-11 66625 intronic  TOM1L2 Novel biology -0.033 4.80E-04 -0.015 0.052 
17 63771079 rs9972944 17q24.1 A G 0.41 0.036 6.87E-10 66595 intronic CEP112 Novel Biology 0.028 0.003 0.004 0.576 
19 31654615 rs6510186*** 19q12 T C 0.26 0.068 3.11E-08 18782 intergenic TSHZ3 Novel Biology 0.004 0.713 0.006 0.492 
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20 39103882 rs6029130 20q12 T C 0.30 0.035 3.50E-08 66497 intergenic MAFB Osteoclast differentiation58 0.027 0.007 0.015 0.083 
21 28773868 rs1452102 21q21.3 T G 0.59 -0.035 1.74E-09 66489 intergenic ADAMTS5 Endochondral Ossification59 -0.029 0.001 -0.015 0.056 
21 36970350 rs9976876 21q22.12 T G 0.45 -0.038 8.01E-11 66514 intronic RUNX1 Osteoclast differentiation60 -0.019 0.031 -0.016 0.041 
21 40350744 rs11910328 21q22.2 A G 0.84 -0.043 2.99E-08 66298 intergenic ETS2 Osteoblast maturation61 -0.028 0.020 -0.028 0.007 
 
* Monomorphic in European cohorts.  ** Reported statistics from the in the meta-analysis of European populations. *** Reported statistics from the meta-analysis in the 30-45 
age-strata. 
 
 
